Accuracy of GenoQuick MTB test in detection of
Diagnosis
GenoQuick MTB
Mycobacterium tuberculosis
and resource-limited settings
diagnostic accuracy
nucleic acid amplification
Journal
SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
04
2022
accepted:
13
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
The objective of the study was to determine the diagnostic performance of the GenoQuick MTB test on heated sputum against the conventional Lowenstein-Jensen Fast, reliable, and easy-to-use tests for tuberculosis diagnosis are essential to achieving the Sustainable Development Goal of diagnosing and treating 90% of tuberculosis patients by 2030. We evaluated the diagnostic performance of the GenoQuick MTB, a polymerase chain reaction-lateral flow test, in Uganda, a resource-constrained, high tuberculosis- and HIV-burden setting. Fresh sputum samples from presumptive tuberculosis patients at Mulago Hospital were tested for Of the 86 tested samples, 30.2% had culture-confirmed pulmonary tuberculosis. Overall, sensitivity was higher for GenoQuick MTB (81%, 95% confidence interval: 60%-93%) than for smear microscopy (69%, 95% confidence interval: 48%-86%). Among people living with HIV, sensitivity was identical for GenoQuick MTB and smear tests (75%, 95% confidence interval: 42%-95%). Contrastingly, smear had a higher overall specificity (98%, 95% confidence interval: 91%-100%) than for GenoQuick MTB (92%, 95% confidence interval: 81%-97%). A similar trend of specificity was observed among the people living with HIV for smear microscopy (100%, 95% CI: 87%-100%) and for GenoQuick MTB (96%, 95% confidence interval: 81%-100%). The GenoQuick MTB test could be a potential tuberculosis diagnostic test given its higher sensitivity. Evaluation of this test in larger studies is recommended.
Identifiants
pubmed: 35993094
doi: 10.1177/20503121221116861
pii: 10.1177_20503121221116861
pmc: PMC9386833
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20503121221116861Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL087713
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128156
Pays : United States
Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):7-10
pubmed: 19145221
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
J Acquir Immune Defic Syndr. 2010 Dec;55(4):446-50
pubmed: 21105258
J Clin Microbiol. 1995 Jul;33(7):1832-4
pubmed: 7665654
J Clin Microbiol. 1995 Dec;33(12):3106-10
pubmed: 8586682
J Glob Infect Dis. 2016 Jan-Mar;8(1):32-40
pubmed: 27013842
Curr Infect Dis Rep. 2012 Feb;14(1):91-101
pubmed: 22143960
Indian J Med Microbiol. 2005 Jan;23(1):29-33
pubmed: 15928418
Int J Tuberc Lung Dis. 2009 Sep;13(9):1130-6
pubmed: 19723403
PLoS Med. 2011 Nov;8(11):e1001120
pubmed: 22087078
Indian J Med Microbiol. 2007 Jan;25(1):43-9
pubmed: 17377352
J Clin Microbiol. 2012 Jun;50(6):2089-91
pubmed: 22422848
J Clin Microbiol. 2013 Jul;51(7):2112-7
pubmed: 23616457
BMC Microbiol. 2010 Mar 31;10:95
pubmed: 20356361
PLoS One. 2011;6(11):e27017
pubmed: 22073241